Matinas Biopharma Holdings, Inc. Appoints James A. Underberg M.D., M.S., Facpm, Facp, Fnyam, Faspc, Fnla to Its Scientific Advisory Board
March 04, 2020 at 07:00 am
Share
Matinas BioPharma Holdings, Inc. announced the appointment of James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA to its Scientific Advisory Board (SAB). Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of General Internal Medicine and Endocrinology at NYU. Dr. Underberg joins Matinas BioPharma’s current MAT9001 SAB members, Christie M. Ballantyne, M.D., John J.P. Kastelein, M.D., Ph.D., FESC, Harold Bays, M.D., and Kevin C. Maki, Ph.D., now representing five of the world’s leading lipid specialists and cardiovascular health experts. Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and Immediate Past-President of the National Lipid Association. He is a Fellow of the National Lipid Association and President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the National Lipid Association, the Foundation of the National Lipid Association, The American Society of Preventive Cardiology and the American Board of Clinical Lipidology. Dr. Underberg also serves on the scientific advisory board of the Familial Hypercholesterolemia (FH) Foundation.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.